Mildronate (Meldonium) – Grindex, 60 tabs per 500 mg
Meldonium, sold under the brand name Mildronate, is a performance-enhancing drug that is the source of much debate in the world of sports doping.
Initially designed in Latvia for use in animals, the World Anti-Doping Agency (WADA) has indicated that this drug is banned in Olympic sports.
Meldonium is primarily manufactured by a Latvian drug company called Grindeks. It is also known as Mildronāts, Quaterine, MET-88, THP, trimethylhydrazinium propionate, and 3-(2,2,2-trimethylhydraziniumyl)propionate,
It is licensed throughout Eastern Europe and Central Asia for a number of conditions, including cardiac complaints. Meldonium is not licensed for use in the United States.
Meldonium is a drug that enhances athletic performance.
One of the early uses of meldonium was in animals. Agricultural workers used the drug specifically to enhance sexual performance and sperm motility of boars. Its license was later expanded for use in humans.
The pharmaceutical company Grendiks, based in Latvia, produced meldonium. With sales of the drug reaching 56 million euros in 2013, it is one of Latvia’s biggest medical exports.
According to the designer of the drug, Ivar Kalvins, chair of the scientific board of the Latvian Institute of Organic Synthesis, meldonium was created to increase the capacity of the body to carry oxygen.
Prior to the use of meldonium for cardiac health issues, the company shipped large quantities of the drug to Soviet troops in Afghanistan between 1979 and 1989.
Due to the mountainous terrain of Afghanistan, Soviet soldiers would take meldonium to increase their endurance in the oxygen-reduced air while carrying large backpacks.
Meldonium is a fatty acid oxidation inhibitor, and it is now principally used for heart conditions, such as angina, heart attack, heart failure, and others.
Other possible uses for meldonium include:
- immune system modulation
- treating stomach ulcers
- treating eye trauma
- treating infections of the lungs and upper respiratory tract